查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718198

内分泌药物市场按治疗领域、药物类别、给药方式、患者年龄层和分销管道划分－2025-2030 年全球预测

Endocrinology Drugs Market by Therapy Area, Drug Class, Mode of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年内分泌治疗市场价值将达571.1亿美元，2024年将成长至610.6亿美元，复合年增长率为7.34%，到2030年将达到938亿美元。

主要市场统计数据
基准年2023年 571.1亿美元
预计2024年 610.6亿美元
预测年份 2030 938亿美元
复合年增长率（%） 7.34%

随着研究的进步以及对荷尔蒙失衡和代谢紊乱的了解加深，内分泌药物已成为现代医疗保健中一个主要且充满活力的领域。这份全面的概述深入探讨了内分泌学市场的变革性演变，揭示了新兴趋势、市场区隔细节和策略区域转变。该报告研究了创新研究、改善患者治疗效果的日益增长的需求以及管理製药行业这一关键领域的法律规范之间的相互作用。

该报告在此基础上清楚地描绘了市场的现状及其近年来的发展。坚定关注临床效益和经济驱动力，使相关人员了解不断的创新如何从根本上改变治疗通讯协定。透过重点案例研究和比较分析，我们探索法规环境、技术突破和以患者为中心的策略如何整合以推动市场快速成长和多样化。

改变内分泌治疗市场

内分泌治疗的市场环境正在发生革命性的变化，重新定义治疗模式。最近的趋势表明，重大的技术进步刺激了研究和开发，从而推出了可提高患者依从性和整体生活品质的新型治疗剂。数据分析和个人化医疗的引入为更有针对性的药物输送系统铺平了道路，确保治疗药物能够精确地适应患者的个别情况。

此外，不断发展的法律规范正在创造一个既能促进创新又能确保病人安全的环境。简化的核准流程和公私合作研究正在加速突破性产品进入市场。这些努力不仅加快了药物开发週期，而且还确保最有效、最安全的治疗方法更快地惠及病患。该行业正在加速使用数位工具和真实数据来推动决策，从而形成更复杂的数据主导策略。

转向综合护理模式以弥合临床研究与患者结果之间的差距也被视为一种变革性变化。这种策略方法对于慢性内分泌疾病的管理尤其重要，因为长期治疗方案和监测至关重要。药物传递的创新，例如先进胰岛素製剂和新型生长激素治疗的开发，就是临床见解如何转化为有影响力的治疗方法的例子。从长远来看，这些合作努力有望带来一个更灵活、更有反应的市场，以便快速应对新的挑战和机会。

更深层的市场细分

深入研究内分泌药物市场区隔可以发现，其多面结构对于策略决策至关重要。该市场已从几个关键维度进行了研究，首先是治疗领域，其中肾上腺疾病、糖尿病、生长迟缓、骨质疏鬆症、脑下垂体疾病和甲状腺疾病等疾病决定了治疗途径。这些领域中的每一个都为药物创新和标靶治疗开发带来了独特的挑战和机会。

透过分析药品类别，可以进一步细分市场。分为抑钙素肽、生长激素治疗剂、胰岛素製剂、口服抗糖尿病药物、口服降血糖药物和副甲状腺素及其类似物，突显了生化方法和患者管理策略的多样性。按药物类别进行区分不仅可以帮助临床研究人员优化治疗计划，还可以帮助製造商根据不断变化的患者需求调整产品系列。

当考虑给药方式时，涵盖吸入、注射和口服药物的多层次方法成为市场区隔的关键因素。这方面反映了配方技术的进步，同时强调患者的舒适度和对治疗方法的依从性。首选的给药方法通常由特定的疾病状况和达到最佳治疗结果所需的药物动力学特征决定。

根据患者年龄进行细分，透过区分成人、老年和儿科群体，进一步丰富了市场分析。了解不同年龄层的荷尔蒙疗法的细微差别，可以製定更精确的治疗计划和临床干预。最后，病患取得这些药物的管道（从医院药局到线上药局再到零售药局）为分销动态和市场渗透策略提供了重要的见解。全面了解这些细分维度对于客製化满足临床和消费者需求的产品和服务至关重要。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 糖尿病和甲状腺机能低下症症等荷尔蒙相关疾病的盛行率增加
      • 政府支持政策和报销制度，减轻医疗费用负担
    • 限制因素
      • 对内分泌治疗药物产品召回的担忧
    • 机会
      • 加强科技公司与製药公司在新疗法研发的合作
      • 将远端医疗和远端监控技术融入内分泌药物治疗
    • 任务
      • 内分泌治疗药物的严格法规环境和核准流程
  • 市场区隔分析
    • 治疗领域：肾上腺疾病治疗的普及率不断提高以及更个人化的护理
    • 药物类别：使用口服抗糖尿病药物（SGLT2抑制剂和GLP-1受体拮抗剂）控制血糖
    • 给药方式：口服给药，以提高病人依从性
    • 病患年龄层：对儿科内分泌药物风味配方的偏好日益增加
    • 分销管道：由于宅配服务的便利，网路药局变得越来越重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 内分泌药物市场（依治疗领域）

  • 肾上腺疾病
  • 糖尿病
  • 生长迟缓
  • 骨质疏鬆症
  • 脑下垂体疾病
  • 甲状腺疾病

7. 内分泌药物市场（依药物类别）

  • 抑钙素肽
  • 生长激素
  • 胰岛素
  • 口服抗糖尿病药物
  • 口服抗高血糖药物
  • 副甲状腺素及其类似物

8. 内分泌治疗市场（依给药方式）

  • 可吸入
  • 注射
  • 口服

9. 内分泌治疗市场（依患者年龄层）

  • 对于成年人
  • 老年人
  • 小儿科

第 10 章内分泌治疗市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章：美洲内分泌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12.亚太内分泌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲内分泌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Ascendis Pharma A/S
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CHIESI Farmaceutici SpA
  • Eli Lilly and Company
  • Endo, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hanmi Pharm Co., Ltd.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • MacroGenics, Inc.
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Precigen, Inc.
  • Sanofi SA
  • Shenzhen Microchip Biotechnology Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-D1342F184FD3

The Endocrinology Drugs Market was valued at USD 57.11 billion in 2023 and is projected to grow to USD 61.06 billion in 2024, with a CAGR of 7.34%, reaching USD 93.80 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 57.11 billion
Estimated Year [2024] USD 61.06 billion
Forecast Year [2030] USD 93.80 billion
CAGR (%) 7.34%

Endocrinology drugs have emerged as both a necessity and a dynamic landscape in modern healthcare, driven by advancements in research and a deepening understanding of hormonal imbalances and metabolic disorders. In this comprehensive overview, we delve into the transformative evolution of the endocrine market while elucidating emerging trends, market segmentation specifics, and strategic regional shifts. The analysis provided here highlights the interplay between innovative research, the rising demand for improved patient outcomes, and the regulatory frameworks that govern this critical sector of the pharmaceutical industry.

This report sets the foundation by establishing a clear picture of the market's current state and its evolution over recent years. With a robust focus on clinical benefits and economic drivers, stakeholders can appreciate how continuous innovation is fundamentally altering treatment protocols. Through focused case studies and comparative analyses, the text explores how regulatory environments, technological breakthroughs, and patient-centric strategies are converging to facilitate rapid growth and market diversification.

Transformative Shifts in the Endocrinology Drugs Landscape

The market landscape for endocrinology drugs is undergoing revolutionary changes that are redefining treatment paradigms. In recent years, significant technological advancements have spurred research and development, leading to the introduction of novel therapeutic agents that improve patient compliance and overall quality of life. The infusion of data analytics and personalized medicine is paving the way for more targeted drug delivery systems, ensuring that therapies are precisely calibrated to individual patient profiles.

Furthermore, evolving regulatory frameworks have created an environment that fosters innovation while ensuring patient safety. The adoption of streamlined approval processes and collaborative research between public and private organizations serves to accelerate market entry for breakthrough products. These initiatives not only expedite the drug development cycle but also ensure that the most effective and safe therapies reach patients more rapidly. The industry is increasingly leveraging digital tools and real-world data to drive decision-making, a development that has led to more refined and data-driven strategies.

Another transformative shift observed is the move towards integrated care models that bridge the gap between clinical research and patient outcomes. This strategic approach is particularly significant in managing chronic endocrine diseases, where long-term treatment protocols and monitoring are essential. Innovations in drug delivery, such as the development of advanced insulin formulations and novel growth hormone therapies, are examples of how clinical insights are being translated into impactful treatments. Over time, these concerted efforts are expected to lead to a more agile and responsive market that is capable of adapting swiftly to new challenges and opportunities.

Deep Dive into Market Segmentation Insights

A deep dive into the segmentation of the endocrinology drugs market reveals a multifaceted structure that is crucial for strategic decision-making. The market is studied across several critical dimensions, starting with therapy areas where conditions such as adrenal disorders, diabetes, growth disorders, osteoporosis, pituitary disorders, and thyroid disorders define treatment pathways. Each of these areas presents unique challenges and opportunities for pharmaceutical innovation and targeted therapeutic development.

Analyzing the market from the perspective of drug class further refines this segmentation. The categorization into calcitonin peptides, growth hormone therapies, insulin formulations, oral antidiabetics, oral hypoglycemics, as well as parathyroid hormones and analogs, underscores the diversity in biochemical approaches and patient management strategies. The differentiation based on drug class not only aids clinical researchers in optimizing treatment plans but also supports manufacturers in aligning their product portfolios with evolving patient needs.

When examining the mode of administration, a layered approach that encompasses inhalable, injectable, and oral medications emerges as a pivotal factor in market segmentation. This dimension highlights patient comfort and adherence to treatment regimens, while also reflecting advancements in formulation technology. The preferred mode of administration is frequently dictated by the specific pathology and the requisite pharmacokinetic profile required to achieve optimal therapeutic outcomes.

Segmentation based on patient age further enriches the market analysis by distinguishing between adult, geriatric, and pediatric groups. Recognizing the nuances in hormonal therapies for different age demographics allows for more precise therapeutic planning and clinical interventions. Lastly, the channel through which patients access these medications-ranging from hospital pharmacies to online and retail pharmacies-offers critical insights into distribution dynamics and market penetration strategies. An overall view of these segmentation dimensions is essential for tailoring products and services that are responsive to both clinical and consumer demands.

Based on Therapy Area, market is studied across Adrenal Disorders, Diabetes, Growth Disorders, Osteoporosis, Pituitary Disorders, and Thyroid Disorders.

Based on Drug Class, market is studied across Calcitonin Peptides, Growth Hormone, Insulin, Oral Antidiabetics, Oral Hypoglycemics, and Parathyroid Hormones & Analogs.

Based on Mode of Administration, market is studied across Inhalable, Injectable, and Oral.

Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Dynamics Shaping the Market

A comprehensive evaluation of regional dynamics underscores the importance of geographical factors in shaping the endocrinology drugs market. The Americas region has consistently showcased robust growth, driven by high rates of technological adoption and a strong emphasis on patient care innovations. Regulatory reforms in several countries within this region encourage the swift integration of novel therapies into existing healthcare systems.

In the expansive territory of Europe, the Middle East and Africa, there is a visible trend toward modernization along with an increasing adoption of evidence-based practices. This region is characterized by a complex regulatory environment that is rapidly evolving to accommodate breakthrough therapies. Companies operating within these regions are increasingly aligning their strategies to meet the stringent requirements of diverse markets, making significant strides in both research collaborations and distribution innovations.

The Asia-Pacific region is witnessing accelerated growth attributed to a large patient base and rising healthcare investments. The blend of urbanization and improved healthcare infrastructure in emerging economies within this territory is fueling demand for advanced endocrinology drugs. As the market continues to mature, enhanced regulatory frameworks and increased healthcare awareness are expected to further drive expansion throughout the region. These regional analyses collectively provide a broad yet detailed picture of how geographical considerations are integral to market planning and strategic positioning in the current global landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Steering Growth and Innovation

The role of leading companies in driving market innovation and expanding therapeutic options cannot be overstated. The competitive landscape features renowned multinational corporations and agile biopharmaceutical innovators who are continually pushing the boundaries of research and development. Companies such as Abbott Laboratories and AbbVie Inc. stand out as pioneers in leveraging cutting-edge technology and precision medicine in their product development pipelines. Additionally, firms like Ascendis Pharma A/S and AstraZeneca PLC are well-recognized for their contributions to endocrinology through both novel formulations and sustained clinical trials.

Other major players including Bayer AG and Biocon Limited are also making significant inroads in this space, with a strong emphasis on quality improvements and therapeutic efficacy. Firms such as Boehringer Ingelheim International GmbH and Bristol-Myers Squibb Company have built reputations for innovative drug development processes that have transformed patient care standards. CHIESI Farmaceutici S.p.A. alongside Eli Lilly and Company further exemplify the sector's commitment to research excellence and regulatory adherence.

Moreover, companies like Endo, Inc. and F. Hoffmann-La Roche Ltd. continue to set benchmarks in clinical research and market penetration. The activities of influential industry leaders such as GlaxoSmithKline PLC and Hanmi Pharm Co., Ltd. are reflective of the broader ethos driving the market toward more personalized medication regimes. Ipsen Pharma and Johnson & Johnson Services, Inc. have also carved out significant market segments through strategic acquisitions and innovation. Emerging firms, including MacroGenics, Inc. and MannKind Corporation, bring fresh perspectives that contribute to the dynamic evolution of the industry.

Industry giants such as Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S play central roles in facilitating the transition to next-generation therapies with their advanced research capabilities. The innovative approaches of Oramed Pharmaceuticals Inc. and Pfizer Inc. in developing novel drug classes provide valuable insights into the shifting market dynamics. This landscape is further enriched by the pioneering work of companies like Precigen, Inc. and Sanofi S.A, which continuously refine their product portfolios to meet emerging patient needs. In addition, organizations such as Shenzhen Microchip Biotechnology Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. contribute immensely to the widespread dissemination and accessibility of endocrinology drugs. Collectively, these companies are at the forefront of fostering innovations that are set to redefine treatment paradigms across global markets.

The report delves into recent significant developments in the Endocrinology Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ascendis Pharma A/S, AstraZeneca PLC, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CHIESI Farmaceutici S.p.A., Eli Lilly and Company, Endo, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hanmi Pharm Co., Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., MacroGenics, Inc., MannKind Corporation, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Precigen, Inc., Sanofi S.A, Shenzhen Microchip Biotechnology Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders, the insights provided in this extensive review offer a significant opportunity to refine strategic approaches and benchmark against evolving market trends. It is imperative for companies to cultivate robust research and development pipelines while embracing innovative technologies that enable more accurate and efficient drug delivery solutions. One actionable recommendation is to prioritize investments in personalized medicine and digital health solutions that facilitate real-time data analytics, thereby enhancing patient monitoring and treatment compliance.

Furthermore, engaging in cross-sector collaborations and public-private partnerships can be instrumental in catalyzing development processes and reducing time-to-market for breakthrough therapies. Leveraging advanced analytics and artificial intelligence to optimize clinical trial designs and patient recruitment strategies stands as a critical pathway to enhancing research outcomes. Industry leaders should also consider diversifying distribution strategies by aligning with digital platforms, as well as optimizing traditional retail and hospital-based channels, to maximize product accessibility and market penetration.

Another strategic recommendation involves tailoring product portfolios to meet the distinct needs of various market segments. By infusing research with insights about therapy areas, drug classes, patient demographics, and preferred modes of administration, companies can craft targeted approaches that yield high therapeutic efficacy and improved patient outcomes. Leader organizations are encouraged to foster an environment of continuous innovation, ensuring that their offerings evolve in tandem with shifting regulatory landscapes and evolving consumer expectations. By integrating these strategic imperatives, companies can not only secure a competitive advantage but also position themselves as pioneers in the rapidly evolving endocrinology drugs market.

Conclusion: Summarizing Key Insights and Future Outlook

The analysis presented in this summary brings into focus the myriad factors that are shaping the future of the endocrinology drugs market. In summary, the industry is witnessing a confluence of technological innovations, regulatory reforms, and patient-centric strategies that synergistically drive market growth. A systematic approach to understanding market segmentation-whether by therapy area, drug class, mode of administration, patient age, or distribution channel-reveals targeted opportunities that companies can harness to refine their product offerings and market strategies.

Regional insights further underscore the importance of adopting a localized strategy that respects the diverse market dynamics of the Americas, Europe, the Middle East and Africa, and the Asia-Pacific. These geographically tailored strategies are imperative for companies aiming to capitalize on region-specific trends, regulatory environments, and patient demographics. Moreover, the role played by leading companies in the evolution of this market cannot be underestimated. Their pioneering work in research and innovation sets a high benchmark for the industry, pushing the boundaries continuously in pursuit of improved patient outcomes.

As the market continues to evolve, the integration of advanced digital tools, strategic investments in research, and robust partnerships emerges as the way forward. This confluence of factors not only creates a fertile ground for innovation but also lays the foundation for a more agile, responsive, and patient-focused healthcare system. In conclusion, the comprehensive insights shared in this summary serve as a guiding framework for stakeholders looking to navigate and succeed in this dynamic industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of hormone-related disorders such as diabetes and thyroid imbalances
      • 5.1.1.2. Supportive government policies and reimbursement schemes enhancing the affordability of treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with product recall of endocrinology drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising collaborations between technology firms and drug manufacturers for R & D of new treatment
      • 5.1.3.2. Integrating telemedicine and remote monitoring technologies with endocrinology drug treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environments and approval processes for endocrinology drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Area: Growing prevalence of adrenal disorders treatment for more personalized treatment
    • 5.2.2. Drug Class: Utilization of oral antidiabetics for glycemic control due to SGLT2 inhibitors and GLP-1 receptor
    • 5.2.3. Mode of Administration: Adoption of oral endocrinology drugs for improving patient adherence
    • 5.2.4. Patient Age Group: Rising preference for flavorful formulations in pediatric endocrinology medications
    • 5.2.5. Distribution Channel: Increasing significance of online pharmacies due to ease of home delivery services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endocrinology Drugs Market, by Therapy Area

  • 6.1. Introduction
  • 6.2. Adrenal Disorders
  • 6.3. Diabetes
  • 6.4. Growth Disorders
  • 6.5. Osteoporosis
  • 6.6. Pituitary Disorders
  • 6.7. Thyroid Disorders

7. Endocrinology Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Calcitonin Peptides
  • 7.3. Growth Hormone
  • 7.4. Insulin
  • 7.5. Oral Antidiabetics
  • 7.6. Oral Hypoglycemics
  • 7.7. Parathyroid Hormones & Analogs

8. Endocrinology Drugs Market, by Mode of Administration

  • 8.1. Introduction
  • 8.2. Inhalable
  • 8.3. Injectable
  • 8.4. Oral

9. Endocrinology Drugs Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Endocrinology Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Endocrinology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Endocrinology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Endocrinology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. AdipoPharma secures funding for phase 1 trials of type 2 diabetes insulin resistance drug
    • 14.3.2. Eton Pharmaceuticals acquires Increlex from Ipsen for enhancing its pediatric endocrinology portfolio
    • 14.3.3. MITEM PHARMA's strategic acquisition of DESFERAL enhances drug accessibility for serious hematological conditions
    • 14.3.4. FDA approval of Ascendis Pharma's Yorvipath signals new hope for hypoparathyroidism treatment
    • 14.3.5. AstraZeneca's strategic acquisition of Amolyt Pharma enhances rare disease pipeline with groundbreaking endocrinology treatment
    • 14.3.6. Valendo Health secures USD 4 million in seed funding and partnered with Cecelia Health and Advanced Metabolic Care
    • 14.3.7. Henlius and Sermonix announce strategic collaboration and exclusive license agreements for novel endocrine therapy lasofoxifene
    • 14.3.8. Specialised Therapeutics expands endocrinology portfolio through exclusive agreement with Ascendis Pharma for distribution in Oceania and Southeast Asia
    • 14.3.9. Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Sanofi S.A.
    • 14.4.2. Novo Nordisk A/S
    • 14.4.3. Eli Lilly and Company
    • 14.4.4. AstraZeneca PLC

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Ascendis Pharma A/S
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biocon Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. CHIESI Farmaceutici S.p.A.
  • 10. Eli Lilly and Company
  • 11. Endo, Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Hanmi Pharm Co., Ltd.
  • 15. Ipsen Pharma
  • 16. Johnson & Johnson Services, Inc.
  • 17. MacroGenics, Inc.
  • 18. MannKind Corporation
  • 19. Merck & Co., Inc.
  • 20. Novartis AG
  • 21. Novo Nordisk A/S
  • 22. Oramed Pharmaceuticals Inc.
  • 23. Pfizer Inc.
  • 24. Precigen, Inc.
  • 25. Sanofi S.A
  • 26. Shenzhen Microchip Biotechnology Co., Ltd.
  • 27. Sun Pharmaceutical Industries Limited
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ENDOCRINOLOGY DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. ENDOCRINOLOGY DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. ENDOCRINOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. ENDOCRINOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOCRINOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023